Drugs

, Volume 37, Issue 2, pp 116–122 | Cite as

Thrombolysis

An Approach Still on the Move
  • Marc Verstraete
Leading Article
  • 7 Downloads

Keywords

Acute Myocardial Infarction Plasminogen Activator Streptokinase Thrombolytic Agent Type Plasminogen Activator 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. Biochemistry 25: 4033–4040, 1986PubMedCrossRefGoogle Scholar
  2. Blasko G, Berentey E, Harsanyi A, Sas G. Intracoronarily administered prostacyclin and streptokinase for treatment of myocardial infarction. Advances in Prostaglandin Thromboxane Leukotriene Research 11: 385–390, 1983Google Scholar
  3. Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science 229: 765–767, 1985PubMedCrossRefGoogle Scholar
  4. Cambier P, Van de Werf F, Larsen GR, Collen D. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. Journal of Cardiovascular Pharmacology 11: 468–472, 1988PubMedCrossRefGoogle Scholar
  5. Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, et al. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 74: 583–587, 1986PubMedCrossRefGoogle Scholar
  6. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 76: 142–154, 1987PubMedCrossRefGoogle Scholar
  7. Collen D, Stassen JM, Stump DC, Verstraete M. In vivo synergism of thrombolytic agents. Circulation 74: 838–842, 1986aPubMedCrossRefGoogle Scholar
  8. Collen D, Stump DC, Van de Werf F. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. American Heart Journal 112: 1083–1084, 1986bPubMedCrossRefGoogle Scholar
  9. Collen D, Van de Werf F. Coronary thrombolysis with low dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) in man. American Journal of Cardiology 60: 431–444, 1987PubMedCrossRefGoogle Scholar
  10. Coller BS, Folts JD, Scudder LE, Smith SR. Anti-thrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 68: 783–786, 1986PubMedGoogle Scholar
  11. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks binding of fibrinogen to platelets, produces a thromboasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. Journal of Clinical Investigation 12: 325–338, 1983CrossRefGoogle Scholar
  12. DeWood MA, Spores J, Notske R, Mousser LT, Burroughs R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. New England Journal of Medicine 303: 897–902, 1980PubMedCrossRefGoogle Scholar
  13. European Cooperative Study Group. Streptokinase in acute myocardial infarction. New England Journal of Medicine 301: 797–802, 1979CrossRefGoogle Scholar
  14. Fox KAA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, et al. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 72: 1346–1354, 1985PubMedCrossRefGoogle Scholar
  15. Garabedian HD, Gold HK, Leinbach RC, Johns JA, Yasuda T, et al. Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Journal of the American College of Cardiology 9: 599–607, 1987PubMedCrossRefGoogle Scholar
  16. Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, et al. Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. Thrombosis Research 50: 121–133, 1988PubMedCrossRefGoogle Scholar
  17. Gheysen D, Lijnen HR, Piérard L, de Foresta F, Demarsin E, et al. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator (t-PA) with a truncated single-chain urokinase-type plasminogen activator. Journal of Biological Chemistry 262: 11779–11784, 1987PubMedGoogle Scholar
  18. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 77: 670–677, 1988PubMedCrossRefGoogle Scholar
  19. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 73: 347–352, 1986PubMedCrossRefGoogle Scholar
  20. Haber E, Runge M, Bode C, Branscomb B, Schnee J, et al. Antibody targeted fibrinolysis. Abstract 924. Thrombosis and Haemostasis 58: 253, 1987Google Scholar
  21. ISIS-2. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Second International Study of Infarct Survival Collaborative Group. Lancet 2: 349–360, 1988Google Scholar
  22. Kasper W, Meinertz T, Hohnloser S, Engler H, Hasler C, et al. Coronary thrombolysis in man with pro-urokinase improved efficiency with low dose urokinase. Klinische Wochenschrift 66: 109–114, 1988PubMedGoogle Scholar
  23. Krause J. Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis 2: 133–142, 1988Google Scholar
  24. Larsen GR, Metzger M, Blue Y, Henderson K. Pharmacokinetics of genetically modified t-PA in the rat. Abstract 1815. Thrombosis and Haemostasis 57: 491, 1987Google Scholar
  25. Lau D, Kuzma G, Wei CM, Livingston DJ, Hsiung N. A modified human tissue plasminogen activator with extended half-live in vivo. Biotechnology 5: 953–958, 1987CrossRefGoogle Scholar
  26. Lijnen HR, Nelles L, Van Hoef B, Demarsin E, Collen D. Characterization of a chimaeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of urokinase-type plasminogen activator. Journal of Biological Chemistry (in press), 1988Google Scholar
  27. Mueller HS, Rao AK, Forman SA, TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. Journal of the American College of Cardiology 10: 479–490, 1987PubMedCrossRefGoogle Scholar
  28. Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of recombihant human single-chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. Journal of Biological Chemistry 262: 5682–5689, 1987aPubMedGoogle Scholar
  29. Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. Journal of Biological Chemistry 262: 10855–10862, 1987bPubMedGoogle Scholar
  30. Pâques EP, Stöhr HA, Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin. Thrombosis Research 42: 797–807, 1986PubMedCrossRefGoogle Scholar
  31. Piérard L, Jacobs P, Gheysen D, Hoylaerts M, André B, et al. Mutant and chimeric recombinant plasminogen activators: production of eukaryotic cells and preliminary characterization. Journal of Biological Chemistry 262: 11771–11778, 1987PubMedGoogle Scholar
  32. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, et al. for the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. Journal of the American College of Cardiology 11: 1–11, 1988Google Scholar
  33. Raynaud P, Desveaux B. Réocclusion après traitement par l’Actilyse. Archives des Maladies du Coeur et des Vaisseaux 81: 25–32, 1988PubMedGoogle Scholar
  34. Rentrop KP, Blanke H, Karsch KR, Kreuzer H. Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction: comparison with conventionally treated patients. Clinical Cardiology 2: 92–105, 1979PubMedGoogle Scholar
  35. Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proceedings of the National Academy of Sciences of the USA (Washington) 84: 7659–7662, 1987CrossRefGoogle Scholar
  36. Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, et al. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proceedings of the National Academy of Sciences of the USA (Washington) 84: 6904–6908, 1987CrossRefGoogle Scholar
  37. Sharma B, Wyeth RP, Gimenez HJ, Franciosa JA. Intracoronary prostaglandin E1 plus streptokinase in acute myocardial infarction. American Journal of Cardiology 58: 1161–1166, 1986PubMedCrossRefGoogle Scholar
  38. Simoons ML, Arnold AER, Betriu A, de Bono DP, Col J, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1: 197–202, 1988PubMedCrossRefGoogle Scholar
  39. Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 290: 505–508, 1981PubMedCrossRefGoogle Scholar
  40. Spriggs D, Gold HK, Hashimoto Y, Van Houtte E, Vermylen J, et al. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model. Thrombosis and Haemostasis, in press, 1989Google Scholar
  41. Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single chain urokinase-type plasminogen activator. Journal of Biological Chemistry 261: 17120–17126, 1986PubMedGoogle Scholar
  42. Stürzebecher J, Richter M, Markwardt F. Stable acyl-derivatives of tissue-type plasminogen activator. Thrombosis Research 47: 699–703, 1987PubMedCrossRefGoogle Scholar
  43. TIMI Operations Committee, Braunwald E, Knatterud GL, Passamani ER, Robertson TL. Announcement of protocol change in thrombolysis in myocardial infarction. Correspondence. Journal of the American College of Cardiology 9: 467, 1987PubMedCrossRefGoogle Scholar
  44. Topol EJ, Bates ER, Walton Jr JA, Baumann G, Wolfe S, et al. Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. Journal of the American College of Cardiology 10: 1173–1177, 1987PubMedCrossRefGoogle Scholar
  45. Uchida Y, Hanai T, Hasegawa K, Kawamura K, Oshima T. Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Advances in Prostaglandin Thromboxane Leukotriene Research 11: 377–383, 1983Google Scholar
  46. Van de Werf F, Arnold AER, the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator (rt-PA). Effect of intravenous tissue plasminogen activator on infarct size, left ventricular function and survival in patients with acute myocardial infarction. British Medical Journal 297: 1374–1379, 1988PubMedCrossRefGoogle Scholar
  47. Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Annals of Internal Medicine 104: 345–348, 1986aPubMedGoogle Scholar
  48. Van de Werf F, Vanhaecke J, De Geest H, Verstraete M, Collen D. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 74: 1066–1070, 1986bPubMedCrossRefGoogle Scholar
  49. Verstraete M. Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarction. European Heart Journal 6: 586–593, 1985PubMedGoogle Scholar
  50. Verstraete M. The search for the ideal thrombolytic agent. Journal of the American College of Cardiology 10: 4B–10B, 1987PubMedCrossRefGoogle Scholar
  51. Verstraete M. Thrombolysis after myocardial infarction. Erratum. Lancet 1: 763, 1064,1988CrossRefGoogle Scholar
  52. Verstraete M, Arnold AER, Brower RW, Collen D, de Bono DP, et al. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. American Journal of Cardiology 60: 231–237, 1987PubMedCrossRefGoogle Scholar
  53. Verstraete M, Bernard R, Bory M, Brower RW, Collen D, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1: 842–847, 1985PubMedCrossRefGoogle Scholar
  54. Verstraete M, van de Loo J, Jesdinsky HJ (Eds). Streptokinase in acute myocardial infarction. Acta Medica Scandinavica Supplementum 648, 1981Google Scholar
  55. Welzel D, Wolf H. Clinical research on single-chain urokinase-type plasminogen activator (scu-PA) in Germany: results in patients with acute myocardial infarction (AMI). Abstract 160. Thrombosis and Haemostasis 58: 47, 1987Google Scholar
  56. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. European Heart Journal 6: 556–585, 1985PubMedGoogle Scholar
  57. Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, et al. Coronary thrombolysis in dogs with synergistic combinations of human tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA). Clinical Research 35: 337A, 1987Google Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • Marc Verstraete
    • 1
  1. 1.Center for Thrombosis and Vascular ResearchUniversity of LeuvenLeuvenBelgium

Personalised recommendations